Literature DB >> 29450466

Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts.

Emanual Maverakis1, Chelsea Ma1, Kanade Shinkai2, David Fiorentino3,4, Jeffrey P Callen5,6, Uwe Wollina7, Angelo Valerio Marzano8, Daniel Wallach9, Kyoungmi Kim10, Courtney Schadt5, Anthony Ormerod11, Maxwell A Fung1, Andrea Steel1, Forum Patel1, Rosie Qin1, Fiona Craig11, Hywel C Williams12, Frank Powell13, Alexander Merleev1, Michelle Y Cheng1.   

Abstract

Importance: Pyoderma gangrenosum is a rare inflammatory skin condition that is difficult to diagnose. Currently, it is a "diagnosis of exclusion," a definition not compatible with clinical decision making or inclusion for clinical trials. Objective: To propose and validate diagnostic criteria for ulcerative pyoderma gangrenosum. Evidence Review: Diagnostic criteria were created following a Delphi consensus exercise using the RAND/UCLA Appropriateness Method. The criteria were validated against peer-reviewed established cases of pyoderma gangrenosum and mimickers using k-fold cross-validation with methods of multiple imputation. Findings: Delphi exercise yielded 1 major criterion-biopsy of ulcer edge demonstrating neutrophilic infiltrate-and 8 minor criteria: (1) exclusion of infection; (2) pathergy; (3) history of inflammatory bowel disease or inflammatory arthritis; (4) history of papule, pustule, or vesicle ulcerating within 4 days of appearing; (5) peripheral erythema, undermining border, and tenderness at ulceration site; (6) multiple ulcerations, at least 1 on an anterior lower leg; (7) cribriform or "wrinkled paper" scar(s) at healed ulcer sites; and (8) decreased ulcer size within 1 month of initiating immunosuppressive medication(s). Receiver operating characteristic analysis revealed that 4 of 8 minor criteria maximized discrimination, yielding sensitivity and specificity of 86% and 90%, respectively. Conclusions and Relevance: This Delphi exercise produced 1 major criterion and 8 minor criteria for the diagnosis of ulcerative pyoderma gangrenosum. The criteria may serve as a guideline for clinicians, allowing for fewer misdiagnoses and improved patient selection for clinical trials.

Entities:  

Mesh:

Year:  2018        PMID: 29450466     DOI: 10.1001/jamadermatol.2017.5980

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  71 in total

Review 1.  [Brief review of the diagnostics of pyoderma gangraenosum].

Authors:  Joachim Dissemond
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

2.  Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy.

Authors:  Giorgia Guaitoli; Federico Piacentini; Claudia Omarini; Alessia Andreotti; Enza Palma; Simona Papi; Chiara De Pietri; Andrea Conti; Stefano Cascinu; Giovanni Tazzioli
Journal:  Breast Cancer       Date:  2018-12-18       Impact factor: 4.239

3.  End stage scurvy in the developed world: A diagnostic conundrum but not to be mistaken for pyoderma gangrenosum.

Authors:  Stephanie T Le; Jenny Z Wang; Claire C Alexanian; Stephanie Y Johng; Forum B Patel; Elizabeth A Wang; Chelsea Ma; Reason Wilken; Michelle Y Cheng; Emanual Maverakis
Journal:  Int Wound J       Date:  2019-06-02       Impact factor: 3.315

4.  Pyoderma gangrenosum confused with congenital preauricular fistula infection: A case report.

Authors:  Yang Zhao; Rou-Yu Fang; Guo-Dong Feng; Ting-Ting Cui; Zhi-Qiang Gao
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

5.  [Differential diagnosis of a vasculitic syndrome of the lower limb].

Authors:  Nikolas Ruffer; Martin Krusche; Marie-Therese Holzer; Christian Hagel; Ina Kötter
Journal:  Z Rheumatol       Date:  2021-07-09       Impact factor: 1.372

6.  The authors reply to: "Doubts about first report of krokodil use in Canada".

Authors:  Feras M Ghazawi; Jennifer Beecker
Journal:  CMAJ       Date:  2020-01-06       Impact factor: 8.262

7.  Clinically inactive pyoderma gangrenosum successfully treated with negative pressure therapy and punch grafting.

Authors:  Raquel Grado Sanz; Elena Conde-Montero; Laura Pérez Jerónimo; Alicia Peral Vázquez; Lorena Recarte Marín; Amparo Galindo Carlos; Juan A Martín Navarro
Journal:  Int Wound J       Date:  2020-01-03       Impact factor: 3.315

8.  A Wound Care Specialist's Approach to Pyoderma Gangrenosum.

Authors:  David Croitoru; Sheida Naderi-Azad; Muskaan Sachdeva; Vincent Piguet; Afsaneh Alavi
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-06-16       Impact factor: 4.730

9.  Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Authors:  Misty M Hobbs; Alex G Ortega-Loayza
Journal:  Int Wound J       Date:  2020-05-06       Impact factor: 3.315

10.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.